Health and Healthcare
Why Pfizer Is Pushing the Dow to All-Time Highs
Published:
Last Updated:
Although the markets were mixed on Thursday, major drug manufacturers proved to be one of the more positive segments on the day. In fact, Pfizer Inc. (NYSE: PFE), Merck & Co., Inc. (NYSE: MRK) and Johnson & Johnson (NYSE: JNJ) proved to be some of the top-performing Dow stocks, helping to push the average to all-time highs, while the S&P 500 and Nasdaq backed off.
Pfizer had the biggest gain out of the group, but it also had the biggest news break on Thursday. Pfizer, along with Astellas, announced late-stage results from their Prosper trial of Xtandi (enzalutamide).
Specifically, the Phase 3 trial was evaluating Xtandi plus androgen deprivation therapy (ADT) versus ADT alone in patients with non-metastatic castration-resistant prostate cancer (CRPC). The trial met its primary endpoint of improved metastasis-free survival.
Looking ahead, the companies intend to discuss the data with global health authorities to potentially support expanding the label for Xtandi to cover all patients with CRPC.
Currently, Xtandi is approved for the treatment of metastatic CRPC based on clinical data from previous studies that showed a statistically significant overall survival benefit versus the placebo in a metastatic CRPC setting. Xtandi has been prescribed to more than 185,000 patients globally since its first approval in 2012.
Neal Shore, M.D., director, CPI, Carolina Urologic Research Center, commented:
Many prostate cancer patients who initiate androgen deprivation therapy will experience disease progression illustrated by a rising PSA level, and currently, there are no FDA-approved treatment options for patients with non-metastatic CRPC until they develop confirmed radiographic metastatic disease.
24/7 Wall St.Mace Rothenberg, M.D., chief development officer, Oncology, Pfizer Global Product Development, added:
We are delighted with the significant results seen in the Prosper study, showing that Xtandi plus ADT delayed clinically detectable metastases compared to ADT alone in patients with non-metastatic CRPC whose only sign of underlying disease was a rapidly rising prostate-specific antigen (PSA) level. We look forward to discussing the data with regulatory authorities. Xtandi is already established as a standard of care for men with metastatic CRPC based on the results of prior studies, such as Affirm and Prevail, which demonstrated that Xtandi delayed disease progression and improved overall survival in men with clinically detectable metastatic disease.
Shares of Pfizer were last seen up 2% at $35.75, with a consensus analyst price target of $37.45 and a 52-week range of $29.83 to $35.84.
Merck and Johnson & Johnson shares each were up less than 2% to $65.88 and $134.25, respectively.
The #1 Thing to Do Before You Claim Social Security (Sponsor)
Choosing the right (or wrong) time to claim Social Security can dramatically change your retirement. So, before making one of the biggest decisions of your financial life, it’s a smart idea to get an extra set of eyes on your complete financial situation.
A financial advisor can help you decide the right Social Security option for you and your family. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.
Click here to match with up to 3 financial pros who would be excited to help you optimize your Social Security outcomes.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
